SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Apr 1, 2026
Aptose Biosciences Inc. (CIK 0000882361)
Date: April 1, 2026 · CIK: 0000882361 · Accession: 0000000000-26-003336
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Aptose Biosciences Inc. Preliminary Proxy Statement on Schedule 14A Filed December 5, 2025 Dear William Rice:
April 1, 2026
William Rice Chief Executive Officer Aptose Biosciences Inc. 66 Wellington Street West, Suite 5300 TD Bank Tower, Box 48 Toronto, Ontario M5K 1E6 Canada
We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Daniel M. Miller, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2026 William Rice Chief Executive Officer Aptose Biosciences Inc. 66 Wellington Street West, Suite 5300 TD Bank Tower, Box 48 Toronto, Ontario M5K 1E6 Canada Re: Aptose Biosciences Inc. Preliminary Proxy Statement on Schedule 14A Filed December 5, 2025 Dear William Rice: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel M. Miller, Esq. </TEXT> </DOCUMENT>